Navigation Links
Lilly Suspends Phase III Trial in Metastatic Melanoma
Date:12/13/2010

INDIANAPOLIS, Dec. 13, 2010 /PRNewswire/ -- Eli Lilly and Company announced today that it has suspended its global Phase III study evaluating tasisulam, an investigational, small-molecule anti-cancer compound, as a second-line treatment for those with unresectable or metastatic melanoma.

Lilly, in consultation with an independent data monitoring committee, recommended a "full clinical hold," because of safety concerns.  A full clinical hold ensures that no new or existing patients in the trial receive additional doses of the compound, allowing researchers the time to fully analyze existing data.

Lilly notified regulatory agencies and contacted all trial investigators to provide details on how to manage individuals enrolled in the trial.

"We are thoroughly reviewing the clinical trial data to understand what modifications to the study protocol or dosing would be needed to improve patient safety on this trial," said Richard Gaynor, M.D., vice president, oncology product development and medical affairs for Lilly.

Lilly continues to develop tasisulam as part of an extensive clinical development program across a wide range of tumors, including soft tissue sarcoma, breast, ovarian and renal cancers, as well as non-small cell lung cancer and acute leukemia. At this time, these trials continue without modification because the dosing of tasisulam is different. Lilly is closely evaluating patient safety within these trials on an ongoing basis.

"We remain committed to Lilly Oncology's active fight against cancer, especially for patients facing cancers where the need for new treatments is especially great," added Gaynor.

The Phase III trial sought to compare the efficacy, safety and tolerability of tasisulam versus paclitaxel, as a second-line treatment for those with metastatic melanoma.  The study enrolled more than 300 patients in 18 countries.  The primary endpoint of this study is overall survival.

Tasi
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
3. Lilly and Glenmark Pharmaceuticals Announce License Agreement
4. Lilly Receives NCQA Design Certification for Depression Care Management Program
5. JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers
6. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
7. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
8. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
9. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
10. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
11. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... completed the sale to Galderma of all rights to ... by Valeant for $1.4 billion in cash, pursuant to ... completed its acquisition of Galderma. "We ... to a company that is firmly committed to the ...
(Date:7/10/2014)... , July 10, 2014 Decision Resources Group ... of the U.S. Food and Drug Administration,s (FDA) approval ... binder Velphoro, which was approved by the FDA in ... kidney disease (CKD) patients on dialysis. Other ... Nephrology (US) Q2 2014 : ...
(Date:1/15/2014)... As health officials across the Midwest warn against the widespread ... Michigan will offer free diagnostic testing for ... to administer tests and, in some cases, fill the matching ... the study. The Grand Rapids, Mich. ...
Breaking Medicine Technology:Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3
... Ala., Nov. 9 Surgical Care Affiliates ("SCA") today ... at 11:00 a.m. Eastern Time on Monday, November 16, ... A 30-day replay will be available approximately an ... (Logo: http://www.newscom.com/cgi-bin/prnh/20080812/CLTU111LOGO ) ...
... Mass., Nov. 9 Boston Scientific Corporation (NYSE: ... the 38th annual Global Congress for Minimally Invasive Gynecology ... Results from two clinical studies will be presented ... systems and mid-urethral sling systems used to treat pelvic ...
Cached Medicine Technology:Boston Scientific's Urology/Gynecology Products Featured in Studies at Global Congress 2Boston Scientific's Urology/Gynecology Products Featured in Studies at Global Congress 3Boston Scientific's Urology/Gynecology Products Featured in Studies at Global Congress 4Boston Scientific's Urology/Gynecology Products Featured in Studies at Global Congress 5
(Date:7/11/2014)... July 11, 2014 Wild by Nature, a ... to announce they are opening a fifth store to be ... Nature offers one of the largest selections of wheat and ... with celiac disease, these stores have become a one-stop shop ... , Gluten sensitivity, and gluten intolerance, is a spectrum of ...
(Date:7/11/2014)... This is a professional and in-depth ... industry in Global and China. The report provides ... applications and industry chain structure. Global market analysis ... a focus on history, developments, trends and competitive ... international and Chinese situation is also offered. , ...
(Date:7/11/2014)... Beach, CA (PRWEB) July 11, 2014 ... pure Artichoke Leaf Extract dietary supplements to aid in ... an action necessary to facilitate metabolism of fat. Formulated ... Superior Labs Artichoke Leaf Extract is available in all-natural, ... pure artichoke extract. , Health Benefits of Artichoke ...
(Date:7/11/2014)... Latham, New York (PRWEB) July 11, 2014 ... imaging as an integral part of each patient’s unique ... detailed analysis of the skin’s health and trouble areas ... a personalized aesthetic plan to be established. , Vectra ... during the consultation appointment, Vectra 3D uses a quick ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 ... email management with its unique Netmail Platform, today ... World Partner Conference (WPC), which will be held ... July 13-17, 2014. During the show, Netmail will ... email management solution that consolidates email security, archiving, ...
Breaking Medicine News(10 mins):Health News:Wild by Nature Opens New Location 2Health News:Cholesterol Industry 2014 Development Trends in Global & China Regions in a New Research Study Available at DeepResearchReports.com 2Health News:Cholesterol Industry 2014 Development Trends in Global & China Regions in a New Research Study Available at DeepResearchReports.com 3Health News:Artichoke Leaf Extract Released by SuperiorLabs Now Available on Amazon.com With 2 Day Prime Shipping 2Health News:Artichoke Leaf Extract Released by SuperiorLabs Now Available on Amazon.com With 2 Day Prime Shipping 3Health News:Williams Rejuva Center Includes Innovative Computer Imaging 2Health News:Netmail Heads to Washington, D.C. to Demonstrate New Release of Netmail 5.3 at WPC 2014 July 13-17, 2014 2Health News:Netmail Heads to Washington, D.C. to Demonstrate New Release of Netmail 5.3 at WPC 2014 July 13-17, 2014 3
... Electronic devices of the future could be smaller, faster, ... discovery by researchers at the Department of Energy,s Oak ... published in Science , involves a method to ... decades have held tremendous promise but have eluded experimental ...
... 17 HealthTronics, Inc. ("HealthTronics") (Nasdaq: HTRN ... ) announced today that HealthTronics has commenced an exchange ... common stock pursuant to their previously-announced definitive agreement dated ... of the exchange offer, Endocare stockholders who validly tender ...
... Inclusion of General Surgeons, Otolaryngologists and , Ophthalmologists ... The American College of Surgeons (ACS) supports legislation ... Zack Space (D-Ohio), which includes the participation of general ... Loan Repayment Program called the Access to Frontline Health ...
... AMERIGROUP Corporation (NYSE: AGP ) today announced that it ... June 24 in Boston, Massachusetts. , , A live webcast ... p.m. Eastern Time, can be accessed on AMERIGROUP,s Web site, ... of the webcast will be available for 30 days after the ...
... ... Center, the most comprehensive program in Orange County. Hoag Voice and Swallowing Center provides ... , ... CA (Vocus) June 17, 2009 -- Hoag Hospital announces the grand opening of ...
... Health-privacy advocates and patient-choice supporters will discuss implications of federal ... on Thursday, June 18 at 9:00 am. Health-policy experts will ... HEALTH-PRIVACY RIGHTS: Which bills will make sure Americans are not ... and track them from cradle to grave and that citizens ...
Cached Medicine News:Health News:ORNL finding could help electronics industry enter new phase 2Health News:HealthTronics, Inc. Commences Exchange Offer for Endocare, Inc. Shares 2Health News:HealthTronics, Inc. Commences Exchange Offer for Endocare, Inc. Shares 3Health News:American College of Surgeons Supports Bill to Create New Frontline Providers Loan Repayment Program 2Health News:Innovative Voice and Swallowing Center Opens in Orange County 2Health News:Innovative Voice and Swallowing Center Opens in Orange County 3
... CryoCath has developed a minimally ... reentrant tachycardia. It delivers a very ... site confirmation, pinpoint site precision, minimal ... thrombus and stenosis., ,Freezor is a ...
The Medtronic CardioRhythm Marinr Catheter is intended for use in diagnostic electrophysiologic procedures. These catheters are designed for recording intracardiac electrograms and temporary pacing a...
... catheter is specifically designed for use with ... EP deflectable NAVI-STAR catheter houses a Biosense ... indicate, in real time, exact location points ... local electrogram information. The NAVI-STAR electro-anatomical navigation ...
For Atrial Mapping. Biosense Webster offers a complete line of specialty 20-pole catheters. The CRISTA CATH 20-pole deflectable catheter is designed for positioning along the crista terminals....
Medicine Products: